ADX10059 in migraine

In our Phase IIa clinical trial in 129 migraine patients, significantly more of the patients who received ADX10059 than those who received placebo were pain-free two hours after dosing (see Fig. 4). ADX10059 had better pain improvement than placebo at all time points up to two hours.

The results of the study suggest that mGluR5 inhibition might play a role in migraine therapy. As a result Addex conducted further studies in migraine prevention to establish whether the compound has a role in this indication. However, data from study 206, a 3-month study in migraine, have shown liver toxicity and led Addex to end development of the long-term use of ADX10059.

mGluR5 & migraine
more about migraine